BiotechTube

Azetukalner

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar Depression

Conditions

Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder

Trial Timeline

Oct 30, 2025 → Aug 1, 2029

NCT ID
NCT07217860

About Azetukalner

Azetukalner is a phase 3 stage product being developed by Xenon Pharmaceuticals for Bipolar Depression. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07217860. Target conditions include Bipolar Depression, Bipolar I Disorder, Bipolar Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT07217860Phase 3Recruiting
NCT06922110Phase 3Recruiting

Competing Products

20 competing products in Bipolar Depression

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
FK949E + PlaceboAstellas PharmaPhase 2/3
65
Escitalopram + Bupropion XLLupin LimitedPhase 3
77
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52

Other Products from Xenon Pharmaceuticals

XEN496Phase 3
74
XEN1101 + PlaceboPhase 3
74
XEN1101 + PlaceboPhase 3
74
XEN1101 + PlaceboPhase 3
74
XEN496 + PlaceboPhase 3
74